Ariel A. Fromowitz, MD

BA, CUNY Queens College, Flushing, NY

MD, New York Medical College, Valhalla, NY

Residency, Internal Medicine, Rutgers, Robert Wood Johnson Medical School, New Brunswick, NJ

Fellowship, Hematology and Medical Oncology, Montefiore Medical Center/ Albert Einstein College of Medicine, Bronx, NY

Fellowship, Stem Cell Transplantation and Cellular Therapy, The University of Texas, MD Anderson Cancer Center, Houston, TX

Dr. Ariel Fromowitz is a triple board-certified (Internal Medicine, Hematology and Medical Oncology) attending physician in the Transplantation and Cellular Therapy program at the University of Maryland, Marlene and Stewart Greenebaum Comprehensive Cancer Center.

He also serves as full-time faculty at the University of Maryland School of Medicine (SOM). 

He received his MD from New York Medical College and completed his Internal Medicine residency at Robert Wood Johnson Medical School. Subsequently, he completed a fellowship in Hematology and Medical Oncology at Montefiore Medical Center/Albert Einstein College of Medicine. Dr. Fromowitz chose to pursue additional focused training and completed an advanced fellowship in the department of Stem Cell Transplantation and Cellular Therapy at the world-renowned MD Anderson Cancer Center. 

His clinical focus is the use of Blood and Marrow Transplantation for hematologic malignancies as well as cellular therapies such as CAR-T therapy for both hematologic malignancies and solid tumors. Dr. Fromowitz has authored and co-authored several abstracts, posters and peer-reviewed publications both nationally and internationally, and is a member of the American Society of Hematology (ASH) and the American Society for Transplantation and Cellular Therapy (ASTCT).

Blood and Marrow Transplantation (BMT), Stem Cell Transplantation, Autologous Stem Cell Transplantation, Allogeneic Stem Cell Transplantation, CAR-T Therapy, Hematologic Malignancies, Leukemia, Lymphoma

Fromowitz A, Verma A. A needed boost against Covid-19 in lymphoma. Nature Cancer. 2022 May;3(5): 526-527. Pubmed PMID: 35624336.

Lee M, Quinn R, Pradhan K, Fedorov K, Levitz D, Fromowitz A, et al. Impact of COVID-19 on Case Fatality Rate of Cancer Patients during the Omicron wave. Cancer Cell. 2022 Apr 11;40(4): 343-345. Pubmed PMID: 35219358.

Shapiro LC, Thakkar A, Campbell ST, Forest SK, Pradhan K, Gonzalez-Lugo JD, Quinn R, Bhagat TD, Choudhary GS, McCort M, Sica RA, Goldfinger M, Goel S, Anampa JD, Levitz D, Fromowitz A, et al. Efficacy of booster doses in augmenting waning immune responses to COVID-19 vaccine in patients with cancer. Cancer Cell. 2022 Jan 10;40(1):3-5. Pubmed PMID: 34838186.

Gulati S, Hsu C, Shah S, Shah P, Zon R, Alsamarai S, Awosika J, Bakouny Z, Bashir B, Beeghly-Fadiel A, Berg S, de-la-Rosa-Martinez D, Doroshow D, Egan P, Fein J, Flora D, Friese C, Fromowitz A, et. al. Systemic Anticancer Therapy and Thromboembolic Outcomes in Hospitalized Patients With Cancer and COVID-19. JAMA Oncol. 2023 Oct 1;9(10): 1390-1400. Pubmed PMID: 37589970.